For decades, Tylenol has been the go-to pain reliever for pregnant women. Doctors often recommended it because it posed fewer known pregnancy risks than ibuprofen or aspirin. Now, one of the country’s largest pharmaceutical legal battles has gained new momentum.
A federal appeals court ruled that Kenvue, the consumer health company that owns the Tylenol brand, must defend lawsuits claiming it failed to warn consumers about a possible link between taking acetaminophen during pregnancy and autism or ADHD in children.
The ruling does not mean Tylenol causes autism. Instead, it allows thousands of lawsuits to move forward after a lower court dismissed many of the claims.
What the Appeals Court Decided
The appeals court found that plaintiffs may continue pursuing claims against Kenvue and its former parent company, Johnson & Johnson.
The lawsuits argue that the companies failed to warn consumers about research suggesting a possible connection between prolonged acetaminophen use during pregnancy and certain neurodevelopmental disorders.
Kenvue strongly disputes those allegations. The company continues to maintain that Tylenol remains safe when consumers use it as directed.
Why This Case Matters
Millions of pregnant women have relied on Tylenol for decades.
Unlike many prescription medications, Tylenol is available over the counter. Physicians have often recommended it because alternative pain relievers can pose greater risks during pregnancy.
That widespread use raises the stakes. If the plaintiffs ultimately prevail, this litigation could become one of the largest pharmaceutical cases in U.S. history.
What Does the Science Say?
The science remains unsettled.
Several observational studies have reported an association between frequent or prolonged acetaminophen use during pregnancy and higher rates of autism spectrum disorder or ADHD in children.
However, an association does not prove causation.
Researchers continue to examine other possible explanations. Genetics, infections during pregnancy, maternal health conditions, fever, and the reason someone took Tylenol may all influence a child’s developmental outcomes.
Large medical organizations, including the American College of Obstetricians and Gynecologists (ACOG), still consider acetaminophen one of the safest pain-relief options during pregnancy when used appropriately and only when medically necessary.
Why Experts Continue to Debate the Issue
Researchers have reached different conclusions.
Some studies suggest that frequent or long-term acetaminophen use may slightly increase the risk of certain developmental disorders.
Other studies found little or no meaningful relationship after researchers adjusted for additional factors.
Most experts agree on one point: researchers need more high-quality studies before anyone can draw firm conclusions.
That uncertainty has fueled both scientific debate and courtroom battles.
Kenvue Stands Behind Tylenol
Kenvue continues to defend Tylenol’s safety record.
The company says decades of research and regulatory reviews support the safety of acetaminophen when consumers follow label directions.
Kenvue also argues that current scientific evidence does not establish a causal relationship between prenatal acetaminophen use and autism.
The company plans to continue defending itself as the lawsuits move through the courts.
What Happens Next?
The appeals court ruling keeps the lawsuits alive. It does not determine who will ultimately win.
Plaintiffs must now present evidence supporting their claims. Kenvue will have the opportunity to challenge that evidence throughout the legal process.
No court has ruled that Tylenol causes autism, and no damages have been awarded.
For consumers, the case highlights how science evolves over time. It also reminds us that a court’s decision to allow a lawsuit to proceed differs from a finding that a product caused harm.
As the litigation continues, families, physicians, and researchers will closely watch for new evidence that could shape one of the most closely followed debates in modern medicine.
